Open
育世博生物科技股份有限公司(Acepodia)專注研發(fā)新世代癌癥細胞免疫療法。育世博應(yīng)用其特有ACC (Antibody-Cell Conjugation)技術(shù)平臺，即「抗體-細胞連結(jié)技術(shù)」，無需基因工程，使用化學(xué)連結(jié)技術(shù)，展現(xiàn)高腫瘤專一、多靶點選擇、低製造成本且安全的特性，發(fā)展一系列應(yīng)用抗體連結(jié)免疫細胞(Antibody-Conjugated Effector cells, ACE)，啟動人體免疫機制，導(dǎo)引清除癌癥細胞之創(chuàng)新治療方案。育世博期望針對多種目前欠缺有效治療方案的實體與血液腫瘤，開發(fā)現(xiàn)成型(Off-the-shelf)細胞治療新藥，陸續(xù)有多項產(chǎn)品進入臨床試驗，其HER2表現(xiàn)陽性腫瘤治療新藥ACE1702已進入人體臨床一期試驗，於美國多個癌癥中心展開收案。其ACE1831為CD20表現(xiàn)陽性血液腫瘤治療新藥，預(yù)計於2021年下半年向美國FDA申請進入人體臨床試驗。
Acepodia is a clinical stage biotech company dedicated to the development of targeted, allogeneic, off-the-shelf cell therapies to eradicate cancers.
Antibody-Cell Conjugation (ACC) platform, its novel technology links tumor-targeting antibodies to the surface proteins of its proprietary immune cells, oNK and γδ T cells. No complicated genetic engineering is required; therefore, the conjugation technology could be powerful, versatile, affordable and safe. The Antibody-Conjugated Effector (ACE) cells significantly increases the avidity with cancer cells, which activates immune system and leads to effectively identifying and eliminating the targeted cancer cells robustly.
Acepodia is a clinical stage biotech company dedicated to the development of targeted, allogeneic, off-the-shelf cell therapies to eradicate cancers.
Antibody-Cell Conjugation (ACC) platform, its novel technology links tumor-targeting antibodies to the surface proteins of its proprietary immune cells, oNK and γδ T cells. No complicated genetic engineering is required; therefore, the conjugation technology could be powerful, versatile, affordable and safe. The Antibody-Conjugated Effector (ACE) cells significantly increases the avidity with cancer cells, which activates immune system and leads to effectively identifying and eliminating the targeted cancer cells robustly.